EBS vs. BOLT, RGLS, FBIO, RIGL, VNDA, VSTM, XOMA, PDSB, IOBT, and RNAC
Should you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include Bolt Biotherapeutics (BOLT), Regulus Therapeutics (RGLS), Fortress Biotech (FBIO), Rigel Pharmaceuticals (RIGL), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), XOMA (XOMA), PDS Biotechnology (PDSB), IO Biotech (IOBT), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical preparations" industry.
Bolt Biotherapeutics (NASDAQ:BOLT) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings, community ranking and analyst recommendations.
Emergent BioSolutions has a net margin of -72.11% compared to Emergent BioSolutions' net margin of -878.58%. Bolt Biotherapeutics' return on equity of -37.35% beat Emergent BioSolutions' return on equity.
Bolt Biotherapeutics currently has a consensus target price of $7.00, suggesting a potential upside of 530.63%. Emergent BioSolutions has a consensus target price of $5.00, suggesting a potential upside of 160.42%. Given Emergent BioSolutions' stronger consensus rating and higher probable upside, research analysts plainly believe Bolt Biotherapeutics is more favorable than Emergent BioSolutions.
In the previous week, Emergent BioSolutions had 2 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 4 mentions for Emergent BioSolutions and 2 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 0.20 beat Emergent BioSolutions' score of -0.16 indicating that Emergent BioSolutions is being referred to more favorably in the news media.
Bolt Biotherapeutics has higher earnings, but lower revenue than Emergent BioSolutions. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.
Emergent BioSolutions received 332 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. However, 68.38% of users gave Bolt Biotherapeutics an outperform vote while only 66.45% of users gave Emergent BioSolutions an outperform vote.
Bolt Biotherapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are held by institutional investors. 28.4% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 1.2% of Emergent BioSolutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Bolt Biotherapeutics and Emergent BioSolutions tied by winning 9 of the 18 factors compared between the two stocks.
Get Emergent BioSolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent BioSolutions Competitors List
Related Companies and Tools
